Biomarkers and Bioactivity in Drug Discovery using a Joint Modelling Approach

Abstract

Biomarkers that are validated and robust are required for the enhancement of diagnosis, the observation of drug-related activity, therapeutic reactions, and as the blueprint for developing safer and more direct therapeutic efforts for a variety of chronic ailments. Various kinds of biomarkers have proven impactful when it comes to the discovery and development of drugs, but the procedure that involves identifying and verifying ailment-specific biomarkers has proven to be hassling. In recent times, there have been some advancements in multiple omics (also known as multi-omics) methods like transcriptomic, cytometry, genomics, proteomics, metabolomics and imaging. These advancements have made it possible for the discovery and development of distinct biomarkers for complicated chronic ailments to be accelerated expeditiously. In spite of the fact that numerous drawbacks still need to be looked into, ongoing efforts for the discovery and improvement of illness-associated biomarkers will go a long way in optimizing decision-making across the entire process of drug development and expand our comprehension of the infection processes. In addition, when the preclinical biomarkers are effectively translated into the clinic, the way will pave well to an equally effective implementation of personalized therapies throughout complicated illness environments to become beneficial to patients, healthcare service providers and the industry of bio-pharma.